Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flumazenil/Naltrexone - Trexapharm

Drug Profile

Flumazenil/Naltrexone - Trexapharm

Alternative Names: Naltrexone/Flumazenil - Trexapharm

Latest Information Update: 15 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trexapharm
  • Class Antidepressants; Antidotes; Antivirals; Benzodiazepinones; Cyclopropanes; Drug withdrawal therapies; Esters; Ethers; Eye disorder therapies; Fluorine compounds; Imidazoles; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
  • Mechanism of Action GABA-A receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Major depressive disorder

Most Recent Events

  • 22 Apr 2021 Clinical trials in Major depressive disorder (In adults, In the elderly) in Australia (SC) (ACTRN12621000310864)
  • 25 Mar 2021 Preclinical trials in Major depressive disorder in Australia (SC) before March 2021
  • 19 Mar 2021 Trexapharm plans a clinical MAC-D trial for Major depressive disorder in April 2021 in Australia (SC, Infusion) (ACTRN12621000310864)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top